UPDATED: OncoMed hits the brakes on PhII pancreatic cancer trial, shares plummet

John Carroll

slammed the on a Phase II study of the stem cell drug tarextumab, citing worsening response rates in the drug arm for cancer, with red flags shooting up for overall survival as well as progression-free survival rates among patients.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2019 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS